Budesonide Treatment for Lymphocytic Colitis

This study has been completed.
Dr. Falk Pharma GmbH
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
First received: September 9, 2005
Last updated: March 29, 2010
Last verified: March 2010
The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

Condition Intervention Phase
Microscopic Colitis
Drug: Budesonide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Budesonide for Treatment of Lymphocytic Colitis

Resource links provided by NLM:

Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • Proportion of patients in clinical remission after 6 weeks

Secondary Outcome Measures:
  • safety
  • quality of life
  • histological improvement

Estimated Enrollment: 40
Study Start Date: January 2002
Study Completion Date: August 2007
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • lymphocytic colitis
  • diarrhea
  • effective contraception
  • written informed consent

Exclusion Criteria:

  • other forms if IBD
  • celiac disease
  • infectious colitis
  • history of colonic surgery
  • use of budesonide, 5-ASA, steroids within th previous 4 weeks
  • pregnancy, lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00180050

Medical Department I, Technical University Hospital
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Dr. Falk Pharma GmbH
Principal Investigator: Stephan Miehlke, Prof. Medical Department I, Technical University Hospital, Dresden, Germany
  More Information

ClinicalTrials.gov Identifier: NCT00180050     History of Changes
Other Study ID Numbers: BLYCK 
Study First Received: September 9, 2005
Last Updated: March 29, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
lymphocytic colitis
microscopic colitis

Additional relevant MeSH terms:
Colitis, Lymphocytic
Colitis, Microscopic
Colonic Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents

ClinicalTrials.gov processed this record on May 25, 2016